exicuretx.com - XCUR Forward P/S Multiple
Exicure, Inc. (XCUR) faces a critical funding shortage and the threat of delisting in the absence of new investments. On GURU.Markets, the projected market cap-to-revenue ratio, where 70.90 represents the current metric level, demonstrates the potential of RNA-based oncology drugs. The company is currently urgently restructuring its R&D pipeline, developing targeted SNA products to overcome the stagnation in clinical trials.
Summary analytical data breakdowns for exicuretx.com (XCUR)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital Exicure, Inc.|XCUR - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Exicure|XCUR - Company Aggregate Debts|Debt to Book Capitalization Ratio Exicure, Inc.|XCUR - Company Long-Term Loans and Borrowings|Company Short-Term Debts Exicure|Quick Liquidity exicuretx.com
- net income and valuation multiples indicators:
XCUR - Company Profit|Projected Future Earnings Exicure, Inc.|XCUR - P/E Multiple|Forward P/E Multiple Exicure|XCUR - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Exicure, Inc.|XCUR - Operating profit before amortization|Net earnings per share (EPS TTM) Exicure|XCUR - Net earnings per share for the last four quarters|Quarterly EPS earnings growth exicuretx.com|XCUR - Net earnings per share growth this year|Expected earnings per share growth for next year Exicure, Inc.
- sales volume and revenue indicators:
Fundamental company analysis:XCUR (Exicure Corp)
Downsizing the workforce to a compact scientific core and transitioning to external contracts minimize costs for Exicure, Inc. (XCUR), focusing capital on development. The ratio of current market capitalization to projected revenue allows for an assessment of market expectations for future sales; therefore, analyzing the company's projected P/S chart helps investors recognize asset overvaluation in a timely manner and avoid buying at local peaks.
Key competitors
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|QGEN: Market Cap to Projected Revenue|Ionis Pharma - Forward P/S Multiple|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA (Avidity Biosciences) - Forward Price-to-Revenue Multiple|CRSP - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple WGS|Market Cap to Projected Revenue RARE (Ultragenyx Pharmaceutical Inc.)|Forward P/S Multiple BEAM|Forward Price-to-Revenue Multiple Sarepta Corp SRPT|Twist Bioscience - Forward Price-to-Revenue Multiple|Forward P/S Multiple 10xgenomics.com TXG|NTLA - Price-to-Projected Revenue Ratio|Forward Price to Sales STOK (Stoke Therapeutics Inc)|BLFS: Forward P/S Multiple|Market Cap to Projected Revenue WVE|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|Market Cap to Projected Revenue SION (sionnatx.com)|Forward P/S Multiple PRME|Forward P/S Multiple Taysha Gene Therapies Inc (TSHA)|Forward P/S Multiple QURE (uniQure Corp)|MeiraGTx Corp (MGTX) - Market Cap to Future Revenue Ratio|RGNX: Forward Price-to-Revenue Multiple|SLDB (solidbio.com) - Market Cap to Projected Revenue|OCGN: Forward P/S Multiple|PACB - Market Cap to Expected Sales Ratio|BNTC (Benitec) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Design Corp (DSGN)|Forward Price-to-Revenue Multiple RCKT (Rocket Pharmaceuticals)|Forward P/S Multiple 4dmoleculartherapeutics.com (FDMT)|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Forward Price to Sales KRRO|Editas - Forward P/S Multiple|Market Cap to Future Revenue Ratio Silence Therapeutics Corp|PRQR (proqr.com) - Forward Price-to-Revenue Multiple|Codexis - Forward Price to Sales|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Nautilus Biotechnology Inc (NAUT) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Market Cap to Projected Revenue|Forward P/S Multiple GBIO (Generation Bio)|BOLD - Forward Price-to-Revenue Multiple|IMNN: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Phio Pharmaceuticals PHIO|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue RNAZ|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple adnas.com (APDN)|Forward Price-to-Revenue Multiple BLUE (bluebird bio)|Forward P/S Multiple immunoprecise.com (IPA)|Price-to-Projected Revenue Ratio Omega OMGA|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS (syros.com) - Market Cap to Projected Revenue|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TCON|UBX (Unity Bio) - Forward P/S Multiple
